MONTREAL, Nov. 26, 2013 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX")
is pleased to announce an exclusive supply, distribution and licensing
agreement with Sandoz Canada for KLOX's innovative and proprietary
LumiCleanseTM System (also known as Lumigel Cleanse) for the treatment of acne
vulgaris, and for its skin rejuvenation LumiBelTM System (also known as Fast & Mild Beauty System) in Canada.
Under the terms of the agreement, Sandoz Canada will be responsible for
all commercial activities for the acne vulgaris LumiCleanseTM System and the skin rejuvenation LumiBelTM System in the Canadian market. KLOX will be responsible for the supply
of both products to Sandoz Canada. The financial terms of the agreement
include upfront and other milestone payments, as well as a profit share
structure based on product sales.
"KLOX became aware of the new focus on the dermatology market for Sandoz
International following their recent acquisition of Fougera. KLOX is
pleased to work with Sandoz Canada, a well-established company in the
pharmaceutical sector with the expertise and network required to bring
our innovative products to patients and clients across the country.
Still today the need for new, safe and efficacious products is large.
Sandoz Canada is committed to building a strong, branded dermatology
franchise and we are proud that our suite of innovative and effective
dermatology products will serve as a flagship for this franchise in
Canada," said Dr. Lise Hébert, President and Chief Executive Officer of
Today's announcement of the licensing agreement for the acne and skin
rejuvenation products follows two important approvals of KLOX's acne
vulgaris products: first the CE marking this month in Europe of the
company's LumiCleanse™ topical photo-converter gel as a Class IIa
Medical Device and the approval of KLOX's acne vulgaris system by
Health Canada in September of this year. With last week's announcement
of the European CE mark approval, KLOX plans on concluding additional
agreements to secure the global reach of its innovative and proprietary
products to the rest of the world. Statistics show that acne vulgaris
affects over 5 million people in Canada, and approximately 150 million
people worldwide. It accounts for over 30% of dermatology visits and
over 40% of those suffering from this disease are looking for
treatments with a better safety and efficacy profile than what is
currently available. In Canada alone, approximately 1.1 million skin
rejuvenation procedures were conducted in 2012.
About the innovative and non-invasive LumiCleanseTM and LumiBelTM products
The LumiCleanseTM System for the treatment of acne vulgaris is comprised of a multi LED
light, used in conjunction with the LumiCleanseTM photoconverter gel to achieve safe and efficacious results in the
treatment of acne vulgaris. This is done by targeting the underlying
problems that lead to acne vulgaris as well as stimulating collagen in
traumatized skin. The system is designed to promote healing in both the
epidermis and deeper in the dermis in a non-invasive manner. Completed
within a 15-minute treatment cycle including preparation, the treatment
requires applications twice a week for a six-week period. The
technology is non-abrasive, non-thermal, and is comfortable for the
patient. In a 90 patient pivotal trial, the LumiCleanseTM System demonstrated efficacy in acne patients and was clinically and
statistically significant on all primary and secondary endpoints, with
an extremely favourable safety profile. The three month extension study
demonstrated a similar effectiveness and safety profile for the second
treated hemiface and persistence of effect was maintained in 92% of the
cohort that had met the primary endpoint with the first treated
hemiface, demonstrating a persistence of effect of at least 6 months.
The LumCleanseTM System is poised to be a first-in-class treatment for patients
suffering from acne vulgaris.
The LumiBelTM System for skin rejuvenation is comprised of the multi-LED light used
in conjunction with the LumiBelTM photoconverter gel to efficiently achieve full face conditioning and
improvement of wrinkles. In the KLOX clinical trial, patients were
treated once a week for four weeks and demonstrated results lasting for
many weeks following the last treatment. Each session is completed
within a 15-minute treatment cycle.
About KLOX Technologies: Leveraging a light-based biophotonic platform
KLOX is focused on the development and commercialization of a unique,
non-invasive biophotonic technology using a primary device consisting
of a multiple LED light that interacts with an oxygen-rich gel
containing light-trapping molecules. KLOX's cosmetics and medical
devices are destined for the rapidly growing cosmetic, dental,
dermatological and medical markets.
For further information on KLOX, please visit the Company's website www.kloxtechnologies.com or follow us on Twitter @KLOXTech.
Forward Looking Statements
Certain statements contained in this presentation, other than statements
of fact that are independently verifiable at the date hereof, may
constitute forward-looking statements. Examples of such forward looking
statements include those regarding cosmetics and medical devices and
medical applications and clinical trials and the status and related
results thereto, as well those regarding continuing and further
development efforts. Such statements, based as they are on the current
analysis and expectations of management, inherently involve numerous
risks and uncertainties, known and unknown, many of which are beyond
KLOX Technologies Inc.'s control.
SOURCE: KLOX Technologies Inc.
For further information:
KLOX Technologies media contact:
NATIONAL Public Relations
+1 (514) 843-2345
NATIONAL Public Relations
+1 (514) 843-2378